These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4422149)

  • 21. Half a century of L-DOPA.
    Mena MA; Casarejos MJ; Solano RM; de Yébenes JG
    Curr Top Med Chem; 2009; 9(10):880-93. PubMed ID: 19754400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-dopa decarboxylation in chronically treated patients.
    Ward CD; Trombley IK; Calne DB; Kopin IJ
    Neurology; 1984 Feb; 34(2):198-201. PubMed ID: 6538008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
    Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H
    Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 25. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
    Pizzolato G; Cagnin A; Rossato A; Chierichetti F; Fabbri M; Dam M; Ferlin G; Battistin L
    Adv Neurol; 1996; 69():467-73. PubMed ID: 8615167
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease.
    Rosati G; Maioli M; Aiello I; Farris A; Agnetti V
    Eur Neurol; 1976; 14(3):229-39. PubMed ID: 1278195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Some anomalies in the L-DOPA response: recent biochemical studies.
    Sandler M
    Adv Neurol; 1974; 5():259-63. PubMed ID: 4440575
    [No Abstract]   [Full Text] [Related]  

  • 28. Systemic activity of orally administered L-dopa in the elderly Parkinson patient.
    Evans MA; Triggs EJ; Broe GA; Saines N
    Eur J Clin Pharmacol; 1980; 17(3):215-21. PubMed ID: 7363934
    [No Abstract]   [Full Text] [Related]  

  • 29. Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
    Rodgers KJ; Hume PM; Morris JG; Dean RT
    J Neurochem; 2006 Aug; 98(4):1061-7. PubMed ID: 16771833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of mania by L-dopa in a nonbipolar patient.
    Harsch HH; Miller M; Young LD
    J Clin Psychopharmacol; 1985 Dec; 5(6):338-9. PubMed ID: 4066999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [L-dopa treatment in parkinsonism. Biochemical basis (author's transl)].
    Bieniowa A; Kolasa M; Reichowa J
    Przegl Lek; 1976; 33(4):463-7. PubMed ID: 1273343
    [No Abstract]   [Full Text] [Related]  

  • 34. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter: Brown urine, bleach, and L-dopa.
    Devereaux MW; Mancall EL
    N Engl J Med; 1974 Nov; 291(21):1142. PubMed ID: 4419847
    [No Abstract]   [Full Text] [Related]  

  • 36. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
    Perret J; Feuerstein C; Pellat J; Serre F; Gavend M; Tanche M
    Rev Neurol (Paris); 1977 Nov; 133(11):627-36. PubMed ID: 601391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-Dopa and the treatment of extrapyramidal disease.
    Pelton EW; Chase TN
    Adv Pharmacol Chemother; 1975; 13():253-304. PubMed ID: 1106161
    [No Abstract]   [Full Text] [Related]  

  • 39. [Risks of modern therapy for parkinsonism, and their consequences (author's transl)].
    Jörg J; Kleine D
    Nervenarzt; 1979 Jan; 50(1):33-42. PubMed ID: 424033
    [No Abstract]   [Full Text] [Related]  

  • 40. 3-O-methyldopa and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos JL; Mouradian MM; Serrati C; Chase TN
    Neurology; 1987 May; 37(5):856-9. PubMed ID: 3574690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.